23andMe hit with $100M lawsuit from former business partner

Genetic testing company Celmatix filed a $100 million lawsuit against its former business partner 23andMe on Dec. 10, according to CNBC.

In the suit, Celmatix claims 23andMe breached its original contract, causing Celmatix financial setbacks.

The two first began talking about exploring women's fertility in 2015. In the deal, Celmatix offered to pay 23andMe for access to its data and research support. Additionally, the two companies signed an exclusive agreement indicating that 23andMe would not work with competitors in the fertility and infertility space for 10 years.

Celmatix alleges that 23andMe realized the potential of the women's fertility market and its revenue opportunities. It was then that 23andMe CEO Anne Wojcicki allegedly told her team to make the deal with Celmatix "go away."

In 2018, the two companies had terminated their agreement and its exclusivity clause. Since then, Celmatix has had to lay off employees and suspend operations. Additionally, the company has stopped working on its fertility test.

23andMe does not comment on pending litigation, a spokesperson told CNBC.

More articles on consumerism:
Google, Uber alums round out executive team of Optum- and Bezos-backed virtual mental health app
Rutgers, Microsoft develop mobile app to reduce SIDS risk
BCBS report finds consumers still prefer in-person healthcare interactions to digital services: 4 notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers